Unity Biotechnology

Unity Biotechnology is pioneering a novel approach to treating age-related diseases by targeting senescent cells, which accumulate with age and contribute to tissue dysfunction and chronic inflammation. The company's core technology focuses on inhibiting Bcl-xL, a pro-survival protein in senescent cells, to induce their apoptosis. Its most advanced candidate, UBX1325, has shown promising results in mid-stage trials for retinal diseases, positioning Unity at the forefront of the emerging senolytic therapeutics field. The company is publicly traded and continues to advance its pipeline while exploring new indications for its platform.

A senolytic platform focused on developing small molecule inhibitors of Bcl-xL to selectively induce apoptosis in senescent cells, which are implicated in driving age-related diseases and tissue dysfunction.

8 drugs in pipeline

Total raised: $352M

Unity faces competition from other senolytic biotechs (e.g., Cleara Biotech) in a nascent field and, more directly, from established anti-VEGF therapies and next-generation agents in ophthalmology. Its differentiation lies in its first-mover clinical data with a senolytic mechanism and the potential for durable, disease-modifying effects.